Streetbeat News

Regulatory

BDRX

Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) has regained compliance with Nasdaq's minimum bid price requirement. The company received a notification from Nasdaq on July 20, 2023, confirming that it has cured the previously disclosed bid price deficiency.

Portfolio Pulse from Charles Gross

July 24, 2023 | 11:33 am

ADCT

Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals and ADC Therapeutics SA (NYSE:ADCT), announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for ZYNLONTA, a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in China. The BLA has been granted priority review by the NMPA.

Portfolio Pulse from Charles Gross

July 24, 2023 | 11:26 am

EWG

Germany is preparing €20 billion in aid to boost chip production. The funds, to be distributed to both German and international companies by 2027, will be drawn from the Climate and Transformation Fund.

Portfolio Pulse from Charles Gross

July 24, 2023 | 11:21 am

FXI

SPY

Beijing has reportedly asked law firms to moderate the language used to describe China-related business risks in the IPO prospectuses of Chinese companies, according to Reuters. This move could potentially impact the perception of risk associated with investing in Chinese companies listed in the US.

Portfolio Pulse from Charles Gross

July 24, 2023 | 11:19 am

TNGX

Tango Therapeutics has announced the dosing of the first patient in the Phase 1/2 trial of TNG260 in combination with Pembrolizumab for STK11-mutant cancers. This marks a significant step in the development of the drug.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 11:14 am

BCDA

Biocardia has announced that the Independent Data Safety Monitoring Board has completed its prespecified data review for the ongoing Phase 3 Pivotal CardiAMPCell Therapy Heart Failure Trial. The board has recommended pausing the trial pending the one-year follow-up outcomes analysis.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 11:07 am

TNXP

Tonix Pharmaceuticals announced data supporting the memory- and cognition-enhancing effects of TNX-601 ER and TNX-4300. TNX-601 ER is being tested for the treatment of major depressive disorder, with results expected in Q1 2024. TNX-4300 is in preclinical development for mood disorders, Alzheimer's disease, and Parkinson's disease. The findings suggest a role for PPAR-β/δ activation in memory.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 11:05 am

GSK

PFE

ViiV Healthcare, owned by GSK and Pfizer, has received a positive opinion from the European Medicines Agency's CHMP recommending approval of Cabotegravir long-acting injectable and tablets for HIV prevention.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 11:03 am

FXI

China's forex regulator has announced that eligible science and technology enterprises may participate in the cross-border financing facilitation business, according to Reuters.

Portfolio Pulse from Charles Gross

July 24, 2023 | 10:58 am

FXI

China's forex regulator plans to ease restrictions on upfront costs for overseas direct investment. This move will also facilitate payment and use of equity transfer funds and funds raised from overseas listing under domestic reinvestment of foreign-invested enterprises.

Portfolio Pulse from Charles Gross

July 24, 2023 | 10:56 am